NORTH CHICAGO, Ill., Sept. 26, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted approval of Mavyret (glecaprevir/pibrentasvir) to shorten the once-daily treatment duration from 12 to 8 weeks in treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients across all genotypes (GT1-6). In August 2017, Mavyret received regulatory approval in the U.S. as an 8-week, pan-genotypic treatment for treatment-naïve HCV patients without cirrhosis.
“While over 100,000 patients have been prescribed Mavyret for chronic HCV in the US‡, there are still a significant number of patients that need options,” said Janet Hammond, M.D., Ph.D., vice president, general medicine and virology therapeutic area, AbbVie. “This approval provides more HCV patients an option to treat their disease in as little as 8 weeks.”
The label expansion was based on data from the Phase 3b EXPEDITION-8 study, a single-arm, open-label study evaluating the safety and efficacy of Mavyret in treatment-naïve adults with GT1-6 chronic HCV and compensated cirrhosis. In the study, an overall 98 percent (n=335/343) of patients achieved a sustained virologic response 12 weeks after treatment (SVR12).1
“With more than 2.3 million people in the United States still living with chronic HCV, access to shorter-term, 8-week treatment options can help us move closer to achieving the World Health Organization’s goal of eliminating HCV by 2030,” said Robert S. Brown, Jr., M.D., Gladys and Roland Harriman professor of medicine, Weill Cornell Medical College.
In EXPEDITION-8, a single relapse out of 336 patients treated was reported and no patients discontinued treatment due to adverse events.1,2 The adverse reactions reported in greater than or equal to 5 percent of compensated cirrhotic patients (n=343) were fatigue (8%), pruritus (7%), and headache (6%).1 Data from cohort one (GT1,2,4,5,6) was presented last year at The Liver Meeting® 2018 organized by the American Association for the Study of Liver Diseases (AASLD), and data from cohort two (GT3) will be presented at an upcoming medical meeting.
About the EXPEDITION-8 Study
EXPEDITION-8 is a single-arm, open-label, Phase 3b study in treatment-naïve, GT1-6 chronic HCV patients with compensated cirrhosis (n=343) who received Mavyret for 8 weeks.
The primary endpoints are the sustained virologic response 12 weeks after treatment (SVR12) rates in patients across all genotypes in a per-protocol (PP) and intent-to-treat (ITT) population versus respective historical SVR12 rates based on the efficacy of Mavyret for 12 weeks in treatment-naïve patients with compensated cirrhosis. The key secondary efficacy endpoints are the percentages of GT1- 6 patients achieving SVR12 in a PP and ITT population.
Additional information on the clinical trials for MAVYRET is available at www.clinicaltrials.gov/.
About Mavyret (glecaprevir/pibrentasvir)
Mavyret is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus (HCV) infection in adults across all major genotypes (GT1-6).
Mavyret is a pan-genotypic, once-daily, ribavirin-free treatment that combines glecaprevir (100mg), an NS3/4A protease inhibitor, and pibrentasvir (40mg), an NS5A inhibitor, dosed as three tablets taken at the same time once daily with food.
Mavyret is an 8-week, pan-genotypic option for treatment-naïve patients without cirrhosis or with compensated cirrhosis, who comprise the majority of people living with HCV. Mavyret is also approved as a treatment for patients with specific treatment challenges, including those (GT1) not cured by prior treatment experience to either a protease inhibitor or NS5A inhibitor (but not both), and in patients with limited treatment options, such as those with severe chronic kidney disease (CKD) or those with genotype 3 chronic HCV. Mavyret is a pan-genotypic treatment approved for use in patients across all stages of CKD.
Glecaprevir (GLE) was discovered during the ongoing collaboration between AbbVie and Enanta Pharmaceuticals (NASDAQ: ENTA) for HCV protease inhibitors and regimens that include protease inhibitors.
Mavyret (glecaprevir and pibrentasvir) tablets are a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C virus (hep C) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis.
About AbbVie
AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.
For more information, please visit www.abbvie.com/HCV.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words “believe,” “expect,” “anticipate,” “project” and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.
Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie’s operations is set forth in Item 1A, “Risk Factors,” of AbbVie’s 2017 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
_________________________________
*Refers to patients with Child-Pugh A cirrhosis score.
†Liver or kidney transplant recipients are not eligible for an 8-week regimen.
**Patients who achieve a sustained virologic response at 12 weeks post treatment (SVR) are considered cured of hepatitis C.
‡Based on retail and non-retail prescription data from IQVIA week ending 8/11/17-8/2/19.3
1MAVYRET® tablets (glecaprevir/pibrentasvir) Prescribing Information. Chicago, U.S. AbbVie Inc.
2 Brown RS, Hezode C, Wang S, et al. Preliminary Efficacy and Safety of 8-Week Glecaprevir/Pibrentasvir in Patients with HCV Genotype 1–6 Infection and Compensated Cirrhosis: The EXPEDITION-8 Study. Presented at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, U.S., November 13, 2018.
3 Data on file. AbbVie Inc. IQVIA. National Prescription Audit (NPA) week ending 8/11/2017 to week ending 8/2/2019, Weekly Sales Perspective (WSP) and Longitudinal Prescription Claims (LRx) week ending 8/4/2017 to week ending 7/26/2019. August 2019. (IQVIA, all rights reserved).
SOURCE AbbVie
Posted: September 2019
